← Back to Home

Targeting Two Immune Pathways at Once: Orion’s Bispecific Antibody ODM-216 Enters Human Trials for the First Time

ODM-216 has begun testing in patients with advanced solid tumors, bringing Orion’s internally developed biologic into the clinical stage. Whether its dual-target design can deliver anticancer benefits must first be assessed through safety and human pharmacokinetic testing.

By SURL BioNews

Combining two immune-regulatory targets in a single antibody is a new direction for Orion Pharma’s exploration of cancer treatments. That concept has now moved beyond the laboratory: on October 5, the company announced that the first participant with an advanced solid tumor had been dosed with the drug candidate ODM-216, making it the company’s first biologic to enter human trials and its first cancer immunotherapy candidate to reach the clinical stage.

The Phase 1/2 trial, named BICIDES, will evaluate ODM-216’s safety, pharmacokinetics, and preliminary antitumor activity. In other words, alongside recording adverse reactions, the study will examine how drug concentrations change after administration in humans and look for possible signals of efficacy. Orion provided the trial registration number NCT07805252; reports from Nordic Life Science and S&P Capital IQ also confirmed the dosing milestone and the study’s objectives.

ODM-216 is a bispecific antibody that can target both PVRIG and PD-L1. According to the company, both are involved in immune regulation in cancer, and the drug is designed to activate antitumor immune responses. The bispecific design enables a single antibody molecule to recognize two targets, but whether this produces better therapeutic outcomes cannot be inferred from the molecular design alone.

For Orion, this also represents a step toward extending its research and development capabilities into biologics. ODM-216 originated from internal research by teams in Finland, the United Kingdom, and the United States. Participating sites include the biologics research and development center established in Cambridge, United Kingdom, in 2025. Nordic Life Science also described this multinational development pathway, indicating that the clinical advance is backed by the company’s gradual development of capabilities in large-molecule drug development.

ODM-216 is also not the only project in Orion’s cancer immunotherapy development efforts. Both the company announcement and the S&P Capital IQ report noted that its pipeline includes several preclinical candidates. However, the existence of other projects does not yet indicate the success rate of this development pathway; ODM-216, the first to enter human trials, must still be evaluated on the basis of its own clinical data.

The current announcement provides no human efficacy or safety results, nor does it present data such as tumor response rates or duration of response. Dosing the first patient marks the start of trial execution, but is insufficient to determine which patients with cancer might benefit. What can advance this dual-target concept next will be whether participants can tolerate treatment and whether preliminary antitumor signals receive support in subsequent studies.

References

  1. Orion Corporation
  2. Nordic Life Science
  3. S&P Capital IQ / MarketScreener